<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) - Vallejo, M - 2020 | Cochrane Library</title> <meta content="Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) - Vallejo, M - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004102.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection) - Vallejo, M - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004102.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004102.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Trypanocidal drugs for late‐stage, symptomatic Chagas disease (&lt;i&gt;Trypanosoma cruzi&lt;/i&gt; infection)" name="citation_title"/> <meta content="Maite Vallejo" name="citation_author"/> <meta content="Juan Badiano No. 1. Col. Seccion XVI" name="citation_author_institution"/> <meta content="maite_vallejo@yahoo.com.mx" name="citation_author_email"/> <meta content="Pedro PA Reyes" name="citation_author"/> <meta content="Juan Badiano No. 1. Col. Seccion XVI" name="citation_author_institution"/> <meta content="Mireya Martinez Garcia" name="citation_author"/> <meta content="Instituto Nacional de Cardiologia, Ignacio Chavez" name="citation_author_institution"/> <meta content="Alejandro G Gonzalez Garay" name="citation_author"/> <meta content="Instituto Nacional de Pediatría" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004102.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004102.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004102.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004102.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Chagas Cardiomyopathy [drug therapy]; Chagas Disease [*drug therapy]; Chronic Disease; Nifurtimox [adverse effects, *therapeutic use]; Nitroimidazoles [adverse effects, *therapeutic use]; Parasitemia [drug therapy]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Trypanocidal Agents [adverse effects, *therapeutic use]; Trypanosoma cruzi" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004102.pub3&amp;doi=10.1002/14651858.CD004102.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004102\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004102\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004102.pub3",title:"Trypanocidal drugs for late\\u2010stage, symptomatic Chagas disease (\u003ci\u003eTrypanosoma cruzi\u003c/i\u003e infection)",firstPublishedDate:"Dec 11, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004102.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004102.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004102.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004102.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004102.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004102.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004102.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004102.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004102.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004102.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3201 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004102.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/appendices#CD004102-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/table_n/CD004102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/table_n/CD004102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Trypanocidal drugs for late‐stage, symptomatic Chagas disease (<i>Trypanosoma cruzi</i> infection) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#CD004102-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Maite Vallejo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#CD004102-cr-0005">Pedro PA Reyes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#CD004102-cr-0006">Mireya Martinez Garcia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information#CD004102-cr-0007">Alejandro G Gonzalez Garay</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information/en#CD004102-sec-0123">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004102.pub3">https://doi.org/10.1002/14651858.CD004102.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004102-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004102-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004102-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004102-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004102-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004102-abs-0001" lang="en"> <section id="CD004102-sec-0001"> <h3 class="title" id="CD004102-sec-0001">Background</h3> <p>People with Chagas disease may develop progressive and lethal heart conditions. Drugs to eliminate the parasite <i>Trypanosoma</i> <i>cruzi (T cruzi)</i> currently carry limited therapeutic value and are used in the early stages of the disease. Extending the use of these drugs to treat chronic chagasic cardiomyopathy (CCC) has also been proposed. </p> </section> <section id="CD004102-sec-0002"> <h3 class="title" id="CD004102-sec-0002">Objectives</h3> <p>To assess the benefits and harms of nitrofurans and trypanocidal drugs for treating late‐stage, symptomatic Chagas disease and CCC in terms of blood parasite reduction or clearance, mortality, adverse effects, and quality of life. </p> </section> <section id="CD004102-sec-0003"> <h3 class="title" id="CD004102-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS databases on 12 November 2019. We also searched two clinical trials registers, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), on 3 December 2019. </p> </section> <section id="CD004102-sec-0004"> <h3 class="title" id="CD004102-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) assessing trypanocidal drugs versus placebo or no treatment for late‐stage, symptomatic Chagas disease and CCC. </p> </section> <section id="CD004102-sec-0005"> <h3 class="title" id="CD004102-sec-0005">Data collection and analysis</h3> <p>We conducted the reporting of the review according the standard Cochrane methods. Two review authors independently retrieved articles, performed data extraction, and assessed risk of bias. Any disagreements were resolved by a third review author. We contacted<br/>study authors for additional information. </p> </section> <section id="CD004102-sec-0006"> <h3 class="title" id="CD004102-sec-0006">Main results</h3> <p>We included two studies in this review update. One RCT randomly assigned 26 participants to benznidazole 5 mg/kg/day; 27 participants to nifurtimox 5 mg/kg/day; and 24 participants to placebo for 30 days. The second RCT, newly included in this update, randomised 1431 participants to benznidazole 300 mg/day for 40 to 80 days and 1423 participants to placebo. We also identified one ongoing study. </p> <p><b>Benznidazole compared to placebo</b> </p> <p>At five‐year follow‐up, low quality of the evidence suggests that there may be a benefit of benznidazole when compared to placebo for clearance or reduction of antibody titres (risk ratio (RR) 1.25, 95% confidence interval (CI) 1.14 to 1.37; 1 trial; 1896 participants). We are uncertain about the effects of benznidazole for the clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays due to very limited evidence. </p> <p>Low quality of the evidence suggests that when compared to placebo, benznidazole may make little to no difference in the risk of heart failure (RR 0.89, 95% CI 0.69 to 1.14; 1 trial; 2854 participants) and ventricular tachycardia (RR 0.80, 95% CI 0.51 to 1.26; 1 trial; 2854 participants). </p> <p>We found moderate quality of the evidence that adverse events increase with benznidazole when compared to placebo (RR 2.52, 95% CI 2.09 to 3.03; 1 trial; 2854 participants). Adverse effects were observed in 23.9% of patients in the benznidazole group compared to 9.5% in the placebo group. The most frequent adverse effects were: cutaneous rash, gastrointestinal symptoms, and peripheral polyneuropathy. </p> <p>No data were available for the outcomes of pathological demonstration of tissue parasites and quality of life. </p> <p><b>Nifurtimox compared to placebo</b> </p> <p>Data were only available for this comparison for the outcome clearance or reduction of antibody titres, and we are uncertain about the effect due to very limited evidence. </p> <p>Regarding adverse events, one RCT mentioned in a general manner that nifurtimox caused intense adverse events, without any quantification. </p> </section> <section id="CD004102-sec-0007"> <h3 class="title" id="CD004102-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence to support the efficacy of the trypanocidal drugs benznidazole and nifurtimox for late‐stage, symptomatic Chagas disease and CCC. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004102-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004102-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004102-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004102-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004102-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004102-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004102-abs-0002" lang="en"> <h3>Trypanocidal drugs for late‐stage, symptomatic Chagas disease</h3> <p><b>Review question</b> </p> <p>Is trypanocidal drug treatment effective for late‐stage, symptomatic Chagas disease and chronic chagasic cardiomyopathy (CCC)? </p> <p><b>Background</b> </p> <p>Infection with the parasite <i>Trypanosoma cruzi</i> causes American trypanosomiasis, or Chagas disease. The evidence shows that trypanocidal drug treatment, using nitrofuran and imidazole compounds, can cure acute trypanosomiasis cruzi infections. However, it is unclear whether these treatments are effective for late‐stage, symptomatic Chagas disease and CCC. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature for randomised double‐blind controlled clinical trials with or without placebo (dummy treatment) to November 2019. Randomised controlled trials are studies in which participants are assigned to one of two or more treatment groups using a random method. In a double‐blind study, neither the participants nor the researchers know who is receiving a particular treatment. </p> <p><b>Key results</b> </p> <p>We found two trials that looked at treatment of chronic <i>Typanosoma cruzi</i> infection (late‐stage, symptomatic Chagas disease and CCC) with the trypanocidal drugs benznidazole and nifurtimox. After reviewing this limited evidence, we concluded that it is insufficient to support treatment with these drugs. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence ranges between low to very low since a small number of trials were included and the number of participants was limited. More clinical trials are therefore required to evaluate the effect and efficacy of trypanocidal drugs in late‐stage, symptomatic Chagas disease and CCC. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004102-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004102-sec-0092"></div> <h3 class="title" id="CD004102-sec-0093">Implications for practice</h3> <section id="CD004102-sec-0093"> <p>Due to the low quality of the evidence, the efficacy of imidazolic drugs for the treatment of late‐stage, symptomatic Chagas disease remains uncertain. Further studies are needed. </p> </section> <h3 class="title" id="CD004102-sec-0094">Implications for research</h3> <section id="CD004102-sec-0094"> <p>Further RCTs are needed to confirm the efficacy of benznidazole treatment in late‐stage, symptomatic Chagas disease and CCC. The effects of new drugs such as those derived from molecules designed to modify parasite metabolism, but without adverse effects on human physiology – a sort of 'chemical bullet' that would aim to eliminate both blood and tissue parasitism – need to be tested. </p> <p>There also needs to be consideration of the development of better and more precise cure criteria that can be used as outcome measures in such trials, as well as more sensitive and specific diagnostic methods such as those driven from molecular biology in combination with genomic and proteomic techniques. </p> <p>The pathogenesis of chronic complications of <i>T cruzi</i> infection also requires research because the host’s contribution through the immune response could be a cornerstone for the development of late‐stage clinical disease, thereby reducing the relevance of antiparasite treatment as the main therapeutic strategy in advanced disease. </p> <p>Preventive measures such as those applied in Latin America through the Southern Cone, Andean and Central America Initiatives offer the most effective cost‐ and benefits‐based approaches to sustainable control of Chagas disease by reducing acute infection, preventing reinfection and progression to chronic stages with target organ damage. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004102-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004102-sec-0008"></div> <div class="table" id="CD004102-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with both late‐stage, symptomatic Chagas disease and CCC<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> benznidazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Benznidazole</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance or reduction of antibody titres (N)</b> </p> <p><b>(a)</b> at 12 months </p> <p><b>(b)</b> at 2 years </p> <p><b>(c)</b> at 5 years </p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 207 per 1000</b> </p> <p><b>(b) 351 per 1000</b> </p> <p><b>(c) 439 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 395 per 1000</b> </p> <p>(339 to 457)</p> <p><b>(b) 506 per 1000</b> </p> <p>(453 to 562)</p> <p><b>(c) 548 per 1000</b> </p> <p>(500 to 601)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) RR 1.91</b> (1.64 to 2.21) </p> <p><b>(b) RR 1.44</b> </p> <p>(1.29 to 1.60)</p> <p><b>(c) RR 1.25</b> </p> <p>(1.14 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1896 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> <p>(315 to 805)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 31.66</b> </p> <p>(10.56 to 94.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>2</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological demonstration of tissue parasites (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement (N)</b> </p> <p>(a) Heart failure</p> <p>(b) Sustained ventricular tachycardia</p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 86 per 1000</b> </p> <p><b>(b) 29 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 76 per 1000</b> </p> <p>(59 to 98)</p> <p><b>(b) 23 per 1000</b> </p> <p>(15 to 36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) RR 0.89</b> </p> <p>(0.69 to 1.14)</p> <p><b>(b) RR 0.80</b> </p> <p>(0.51 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2854 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>3</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (N)</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> <p>(198 to 287)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.52</b> </p> <p>(2.09 to 3.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2854 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/>Moderate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> Peto odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for methodological limitations due to incomplete outcome reporting and one level due to imprecision (small sample size).<br/><sup>2</sup>Downgraded two levels due to selection bias, performance bias, and incomplete outcome reporting, and one level due to imprecision (small sample size).<br/><sup>3</sup>Downgraded one level for methodological limitations due to incomplete outcome reporting and one level due to imprecision (CI consistent with benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004102-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with both late‐stage, symptomatic Chagas disease and CCC </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> nifurtimox </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nifurtimox</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance or reduction of antibody titres (N)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>704 per 1000</b> </p> <p>(102 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.89</b> </p> <p>(2.44 to 116.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological demonstration of tissue parasites (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to selection bias, performance bias, and incomplete outcome reporting, and one level due to imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004102-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004102-sec-0009"></div> <section id="CD004102-sec-0010"> <h3 class="title" id="CD004102-sec-0010">Description of the condition</h3> <p>American trypanosomiasis, or Chagas disease (<a href="./references#CD004102-bbs2-0029" title="ChagasC . New human trypanosomia. Studies on the morphology and evolutionary cycle of the Schizotrypanum cruzi n.gen., N.sp., ethiological adjunct of a new morbid entity of man [Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n.gen., n.sp., ajente etiolojico de nova entidade morbida do homem]. Memorias do Instituto Oswaldo Cruz1909;1:159-218. [DOI: 10.1590/S0074-02761909000200008]">Chagas 1909</a>), is caused by the flagellate protozoan parasite <i>Trypanosoma cruzi</i> . The geographical distribution of cases of human <i>T cruzi</i> infection extends from the southern United States and Mexico to the south of Argentina. Since 1991, when 18 million people were infected and an estimated 100 million were at risk of contracting the infection (<a href="./references#CD004102-bbs2-0091" title="World Health Organization. Control of Chagas' disease. Report of a WHO Expert Committee. WHO Technical Report Series No. 811. Geneva: World Health Organization, 1991.">WHO 1991</a>), the prevalence of Chagas disease has significantly decreased. Today, there are between 6 to 7 million infected people, most of whom reside in countries in Latin America (<a href="./references#CD004102-bbs2-0093" title="WHO/Department of Control of Neglected Tropical Diseases. Fourth WHO report on neglected tropical diseases. Vol. 1. Geneva: World Health Organization, 2017.">WHO 2017</a>). However, because of the growing population movement, neglected tropical diseases have spread and are becoming a major sanitary problem and an economic burden for endemic and non‐endemic countries (<a href="./references#CD004102-bbs2-0063" title="Rassi A Jr, RassiA , Marin-NetoJ . Chagas disease. Lancet2010;375(9723):1388-402. [DOI: 10.1016/S0140-6736(10)60061-X]">Rassi 2010</a>; <a href="./references#CD004102-bbs2-0070" title="SbaragliniM , VanrellM , BelleraC , BenaimG , CarrilloC , TaleviA , et al. Neglected tropical protozoan diseases: drug repositioning as a rational option. Current Topics in Medicinal Chemistry2016;16(19):2201-22. [DOI: 10.2174/1568026616666160216154309]">Sbaraglini 2016</a>; <a href="./references#CD004102-bbs2-0087" title="UrbinaJ . Recent clinical trials for the etiological treatment of Chronic Chagas disease: advances, challenges and perspectives. Journal of Eukaryotic Microbiology2015;62(1):149-56. [DOI: 10.1111/jeu.12184]">Urbina 2015</a>), such as Canada, the United States, Europe, and the Western Pacific (<a href="./references#CD004102-bbs2-0036" title="FumadóV , JuncosaT , PosadaE , FisaR , GállegoM , GascónJ . Paediatric Chagas in a non-endemic area [Chagas pediátrico en zona no endémica]. Enfermedades Infecciosas y Microbiologia Clinica2014;32(5):293-6. [DOI: 10.1016/j.eimc.2013.04.024]">Fumadó 2014</a>; <a href="./references#CD004102-bbs2-0046" title="ImaiK , MaedaT , SayamaY , OsaM , MikitaK , KuraneI , et al. Chronic Chagas disease with advanced cardiac complications in Japan: case report and literature review. Parasitology International2015;64(5):240-2. [DOI: 10.1016/j.parint.2015.02.005]">Imai 2015</a>; <a href="./references#CD004102-bbs2-0060" title="RamosJ , TorrúsD , AmadorC , JoverF , Pérez-ChacónF , PonceY , et al. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain. Pathogens and Global Health2012;106(6):340-5. [DOI: 10.1179/2047773212Y.0000000039]">Ramos 2012</a>; <a href="./references#CD004102-bbs2-0088" title="Valerio-SallentL , RoureS , BasileL , BallesterosL , SabriàM , RodrigoC , Grupo Metropolitano de estudio del Chagas. A clinical and epidemiological study of the Trypanosoma cruzi infected population in the north metropolitan area of Barcelona [Un estudio clínico-epidemiológico de la población infectada por Trypanosoma cruzi en la zona metropolitana norte de Barcelona]. Revista Clinica Espanola2012;212(7):329-36. [DOI: 10.1016/j.rce.2012.03.017]">Valerio‐Sallent 2012</a>; <a href="./references#CD004102-bbs2-0092" title="WHO/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases 2015. Vol. 3. World Health Organization, 2015.">WHO 2015</a>). The estimated number of infected people in Europe is between 14,000 to 181,000, with most cases being reported in Spain (<a href="./references#CD004102-bbs2-0060" title="RamosJ , TorrúsD , AmadorC , JoverF , Pérez-ChacónF , PonceY , et al. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain. Pathogens and Global Health2012;106(6):340-5. [DOI: 10.1179/2047773212Y.0000000039]">Ramos 2012</a>), Italy (<a href="./references#CD004102-bbs2-0027" title="BricenoL , MoscaW . What is not searched, it is difficult to find: Chagas' disease [Quello che non si cerca difficilmente si trova: la malattia di Chagas]. Giornale Italiano di Cardiologia2016;17(5):343-7. [DOI: 10.1714/2252.24258]">Briceno 2016</a>), and the United Kingdom (<a href="./references#CD004102-bbs2-0037" title="GobbiF , AnghebenA , AnselmiM , PostiglioneC , RepettoE , BuonfrateD , et al. Profile of Trypanosoma cruzi infection in a tropical medicine reference center, Northern Italy. PLOS Neglected Tropical Diseases2014;8(12):e3361. [DOI: 10.1371/journal.pntd.0003361]">Gobbi 2014</a>). </p> <p>The World Health Organization (WHO) reports that the disease has already affected approximately 18 million people around the world, and estimates that 100 million people – 25% of the Latin American population – are at risk of contracting it in the coming years (<a href="./references#CD004102-bbs2-0091" title="World Health Organization. Control of Chagas' disease. Report of a WHO Expert Committee. WHO Technical Report Series No. 811. Geneva: World Health Organization, 1991.">WHO 1991</a>). </p> <p>The infection may be caught by the following routes.</p> <p> <ol id="CD004102-list-0001"> <li> <p>Vectoral transmission. <i>T cruzi</i> parasites, living in the gut of triatomine insects, enter the bloodstream through the bite of the insect. Triatomine bugs live in the cracks and crevices of poor quality houses, especially in rural areas, and emerge at night to bite and extract blood from human hosts. <i>T cruzi</i> parasites are present in insect faeces that subsequently enter the human bloodstream through the wound when it is scratched or rubbed. </p> </li> <li> <p>Transfusion‐linked transmission or iatrogenic transmission. Transfusion with blood infected with <i>T cruzi</i> or allotransplants is the second most important transmission pathway. </p> </li> <li> <p>Vertical transmission from an infected mother to foetus, laboratory accidents, and other routes have also been described (<a href="./references#CD004102-bbs2-0039" title="GrantI , GoldJ , WittnerM , TanowitzH , NathanC , MayerK , et al. Transfusion-associated acute Chagas disease acquired in the United States. Annals of Internal Medicine1989;111:849. [DOI: 10.7326/0003-4819-111-10-849]">Grant 1989</a>; <a href="./references#CD004102-bbs2-0054" title="Monteón-PadillaV , Hernández-BecerrilN , Guzmán-BrachoC , Rosales-EncinaJ , Reyes-LópezPA . American Trypanosomiasis (Chagas' disease) and blood banking in Mexico City: seroprevalence and its potential transfusional transmission risk. Archives of Medical Research1999;30:393-8. [DOI: 10.1016/S0188-4409(99)00062-4]">Monteón‐Padilla 1999</a>; <a href="./references#CD004102-bbs2-0056" title="NickersonP , OurP , SchroederM , SeklaL , JohnstonJ . Transfusion-associeted Trypanosoma cruzi infection in a non-endemic area. Annals of Internal Medicine1989;111:851. [DOI: 10.7326/0003-4819-111-10-851]">Nickerson 1989</a>; <a href="./references#CD004102-bbs2-0059" title="Pinto DiasJC . Natural history of Chagas disease [História natural da doenca de Chagas]. Arquivos Brasileiros de Cardiologia1995;65:359-65.">Pinto 1995</a>; <a href="./references#CD004102-bbs2-0073" title="SchmunisG . Prevention of transfusional Trypanosoma cruzi infection in Latin America. Memorias do Instituto Oswaldo Cruz1999;94(Suppl 1):93-101. [DOI: 10.1590/s0074-02761999000700010]">Schmunis 1999</a>). </p> </li> <li> <p>Oral transmission. This is a more recent form of transmission, through contaminated food (<a href="./references#CD004102-bbs2-0034" title="DiasJ . Elimination of Chagas disease transmission: prospectives. Memorias do Instituto Oswaldo Cruz2009;104(Suppl 1):41-5. [DOI: 10.1590/S0074-02762009000900007]">Dias 2009</a>). </p> </li> </ol> </p> <p>The clinical course of Chagas disease is characterised by an initial 'acute phase', in which parasitaemia is easily demonstrated. During this phase, clinical symptoms may or may not be apparent; however, most people spontaneously improve within six to eight weeks. The presence of circulating parasites confirms the clinical diagnosis. After a few weeks of infection, a lifelong persisting immune response may occur. Chronic infection may result in an 'indeterminate phase' of Chagas disease, which is a long asymptomatic period that can last 30 to 40 years or more. The only proof of infection is a strong immune response with the high titre of anti‐<i>T cruzi</i> antibodies. During this phase, approximately 30% of chronically infected individuals develop irreversible alterations to heart muscles and an enlargement of the intestine (<a href="./references#CD004102-bbs2-0025" title="BarrettoA , AzulL , MadyC , IanniB , De BritoV , BellotiG , et al. Indeterminate form of Chagas' disease. A polymorphic disease [Forma indeterminada da doenca de chagas: Uma doenca polimorfica]. Arquivos Brasileiros de Cardiologia1990;55:347-53. [PMID: 2128863]">Barretto 1990</a>; <a href="./references#CD004102-bbs2-0072" title="SchmunisG . American trypanosomiasis as a public health problem. In: Chagas' Disease and the Nervous System. Washington, DC: Pan American Health Organization, World Health Organization, 1994:3-29.">Schmunis 1994</a>; <a href="./references#CD004102-bbs2-0083" title="TanowitzH , MorrisS , FactorS , WeissL , WittnerM . Parasitic disease of the heart I: acute and chronic Chagas' disease. Cardiovascular Pathology1992;1:7-15. [DOI: 10.1016/1054-8807(92)90004-8]">Tanowitz 1992</a>; <a href="./references#CD004102-bbs2-0091" title="World Health Organization. Control of Chagas' disease. Report of a WHO Expert Committee. WHO Technical Report Series No. 811. Geneva: World Health Organization, 1991.">WHO 1991</a>). This is known as chronic Chagas disease, or late‐stage, symptomatic Chagas disease, and most patients will suffer from chronic chagasic cardiomyopathy (CCC), a specific type of cardiomyopathy characterised by heart failure with bizarre rhythm and/or conduction defects. Unfortunately, during the chronic phase is difficult to observe the presence of parasites either in peripheral blood or tissues, therefore immune serology, and recently immunohistochemistry and biomolecular techniques, are used as diagnostic assays (<a href="./appendices#CD004102-sec-0098">Appendix 1</a>). </p> </section> <section id="CD004102-sec-0011"> <h3 class="title" id="CD004102-sec-0011">Description of the intervention</h3> <p>Although treatment of late‐stage, symptomatic Chagas disease and CCC is the focus of this review, it is important to put the impact of treatment into the broader context of the international efforts to control transmission. In 1991, the Health Ministries of Argentina, Brazil, Bolivia, Chile, Paraguay, and Uruguay created the Southern Cone Initiative, with the objective of eliminating the vector transmission of Chagas disease by the year 2010 and permanent blood donor screening to avoid transfusion‐linked transmission. To date, advances have been made. Because of this initiative, the prevalence of <i>T cruzi</i> infection has been significantly reduced. Uruguay was declared free of vectoral transmission in 1998, and in the other countries active transmission rates have fallen from 96% to 75%, and the infection rate in the young population (below 18 years of age) is now between 0.17% and 1% (<a href="./references#CD004102-bbs2-0028" title="CecereM , CastañeraM , CanaleD , ChuitR , GürtlerR . Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural northwestern Argentina. Revista Panamericana de Salud Publica [Pan American Journal of Public Health]1999;5:392-9. [DOI: 10.1590/s1020-49891999000500003]">Cecere 1999</a>; <a href="./references#CD004102-bbs2-0040" title="HarryM , LemaF , RomañaC . Chagas' disease challenge. Lancet2000;355:236. [DOI: 10.1016/S0140-6736(05)72114-0]">Harry 2000</a>; <a href="./references#CD004102-bbs2-0057" title="Oliveira-FilhoA . Cost-effectiveness analysis in Chagas' disease vector's control intervention. Memorias do Instituto Oswaldo Cruz1989;84 (Suppl IV):409-17. [DOI: 10.1590/S0074-02761989000800074]">Oliveira‐Filho 1989</a>; <a href="./references#CD004102-bbs2-0067" title="RojasA , FerroE , FerreiraM , SimancasL . Chagas disease vector control through different intervention modalities in endemic localities of Paraguay. Bulletin of the World Health Organization1999;77:331-9. [PMID: 10327712]">Rojas 1999</a>; <a href="./references#CD004102-bbs2-0075" title="SchofieldC , DiasJ . The southern cone initiative against Chagas disease. Advances in Parasitology1999;42:1-27. [DOI: 10.1016/s0065-308x(08)60147-5]">Schofield 1999</a>). In 2010, the Pan American Health Organization (PAHO) certified the interruption of transmission by domestic vector and blood transfusion (<a href="./references#CD004102-bbs2-0092" title="WHO/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases 2015. Vol. 3. World Health Organization, 2015.">WHO 2015</a>). </p> <p>It is hoped that through initiatives such as Southern Cone, transmission of <i>T cruzi</i> parasite will be significantly reduced or stopped in the near future. Unfortunately, Chagas disease will continue to impose a high social and economical cost (<a href="./references#CD004102-bbs2-0028" title="CecereM , CastañeraM , CanaleD , ChuitR , GürtlerR . Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural northwestern Argentina. Revista Panamericana de Salud Publica [Pan American Journal of Public Health]1999;5:392-9. [DOI: 10.1590/s1020-49891999000500003]">Cecere 1999</a>; <a href="./references#CD004102-bbs2-0040" title="HarryM , LemaF , RomañaC . Chagas' disease challenge. Lancet2000;355:236. [DOI: 10.1016/S0140-6736(05)72114-0]">Harry 2000</a>; <a href="./references#CD004102-bbs2-0057" title="Oliveira-FilhoA . Cost-effectiveness analysis in Chagas' disease vector's control intervention. Memorias do Instituto Oswaldo Cruz1989;84 (Suppl IV):409-17. [DOI: 10.1590/S0074-02761989000800074]">Oliveira‐Filho 1989</a>; <a href="./references#CD004102-bbs2-0067" title="RojasA , FerroE , FerreiraM , SimancasL . Chagas disease vector control through different intervention modalities in endemic localities of Paraguay. Bulletin of the World Health Organization1999;77:331-9. [PMID: 10327712]">Rojas 1999</a>; <a href="./references#CD004102-bbs2-0075" title="SchofieldC , DiasJ . The southern cone initiative against Chagas disease. Advances in Parasitology1999;42:1-27. [DOI: 10.1016/s0065-308x(08)60147-5]">Schofield 1999</a>). This is because of the long latent phase of the disease (10 to 30 years), and the considerable number of infected people who are currently in the chronic (indeterminate) phase of Chagas disease. A high proportion of people who are currently symptomless will experience symptoms of Chagas disease in the future. Chagas disease burden has been estimated from 300,000 to over 800,000 disability‐adjusted life‐years (DALYs), and its global cost could be up to USD 7.19 billion per year (<a href="./references#CD004102-bbs2-0065" title="RobertsonL , DevleesschauwerB , AlarcónB , Noya GonzálezO , TorgersonP . Trypanosoma cruzi: time for international recognition as a foodborne parasite. PLOS Neglected Tropical Diseases2016;10(6):e000465. [DOI: 10.1371/journal.pntd.0004656]">Robertson 2016</a>; <a href="./references#CD004102-bbs2-0074" title="SchmuñisG . Status of and cost of Chagas disease worldwide. Lancet Infectious Diseases2013;13(4):283-4. [DOI: 10.1016/S1473-3099(13)70032-X]">Schmuñis 2013</a>). Furthermore, the costs of treatment can range between USD 200 in acute cases to more than USD 30,000 in chronic cases; however, the major cost component for lifetime was working days lost, which could range between 44% and 75%, depending on the programme scenario for timely diagnosis and treatment (<a href="./references#CD004102-bbs2-0061" title="RamseyJ , Elizondo-CanoM , Sanchez-GonzálezG , Peña-NievesA , Figueroa-LaraA . Opportunity cost for early treatment of Chagas disease in Mexico. PLOS Neglected Tropical Diseases2014;8(4):e2776. [DOI: 10.1371/journal.pntd.0002776]">Ramsey 2014</a>). In contrast, screening strategies have strengthened since 2006, and vector control investment will cost about USD 720 million (USD 620 to 820 million) per year during 2015 to 2020; however, this may decrease to about USD 450 million (USD 390 to 520 million) per year during 2021 to 2030 as countries move forward in the attack phase (<a href="./references#CD004102-bbs2-0092" title="WHO/Department of control of neglected tropical diseases. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected tropical diseases 2015. Vol. 3. World Health Organization, 2015.">WHO 2015</a>). </p> <p>A report describing 10 years of experience in Honduras, Guatemala, and Bolivia focused on feasible protocols, safety of drug therapy, and treatment effectiveness concluded that it is possible to implement a Chagas disease diagnosis and treatment programme even in limited resource settings; however, treatment effectiveness may be related to differences in patients and parasite populations. New treatments with improved safety profiles, paediatric formulations, and a faster reliable test of cure are urgently needed (<a href="./references#CD004102-bbs2-0094" title="YunO , LimaM , EllmanT , ChambiW , CastilloS , FlevaudL , et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontières. PLOS Neglected Tropical Diseases2009;3(7):e488. [DOI: 10.1371/journal.pntd.0000488]">Yun 2009</a>). </p> </section> <section id="CD004102-sec-0012"> <h3 class="title" id="CD004102-sec-0012">How the intervention might work</h3> <p>Since the eradication of Chagas disease is not a plausible solution (<a href="./references#CD004102-bbs2-0069" title="SalomaoK , Menna-BarretoR , deCastroS . Stairway to heaven or hell? Perspectives and limitations of Chagas disease chemotherapy. Current Topics in Medicinal Chemistry2016;16(20):2266-89. [DOI: 10.2174/1568026616666160413125049]">Salomao 2016</a>; <a href="./references#CD004102-bbs2-0076" title="SchofieldC , JanninJ , SalvatellaR . The future of Chagas disease control. Trends in Parasitology2006;22(12):583-8. [DOI: 10.1016/j.pt.2006.09.011]">Schofield 2006</a>), and control measures such as vector and transfusion control have been shown to be successful, efforts should now be directed towards the development of: 1) an effective prophylactic vaccine (<a href="./references#CD004102-bbs2-0087" title="UrbinaJ . Recent clinical trials for the etiological treatment of Chronic Chagas disease: advances, challenges and perspectives. Journal of Eukaryotic Microbiology2015;62(1):149-56. [DOI: 10.1111/jeu.12184]">Urbina 2015</a>); 2) a molecular biomarker that could help in evaluating the efficacy of treatments; and 3) new compounds to treat chronically symptomatic patients. </p> <p>Trypanocidal drugs have been used in the treatment of Chagas disease since the 1960s (<a href="./references#CD004102-bbs2-0026" title="BrenerZ . Chemotherapy of Trypanosoma cruzi infections. Advances in Pharmacology1975;13:1-44. [DOI: 10.1016/S1054-3589(08)60229-X]">Brener 1975</a>), when nitrofurans and later imidazole drugs were introduced after a long history of therapeutic failures that lasted for 50 years. The trypanocidal drugs nifurtimox (3‐ methyl‐N‐`((5 ‐nitro‐2 furanyl)‐methylene)‐4‐morpholinamine 1,1 dioxide) and benznidazole (2‐nitro‐N‐(phenylmethyl)‐1H‐imidazole‐1‐acetamide) are thought to exert their action by generation of free radicals either in intact cells or <i>Trypanosoma cruzi</i> lysates. However, the mechanisms involved in such reactions are poorly defined (<a href="./references#CD004102-bbs2-0082" title="StoppaniA . The chemotherapy of Chagas disease [Quimioterapia de la enfermedad de Chagas]. Medicina1999;59(Suppl 2):147-65. [PMID: 10668258]">Stoppani 1999</a>). Recently Kubata, who was studying intracellular trypanosomal arachidonic acid and its metabolism in these parasites, found an enzyme that reduced prostanoid metabolites as well as naphthoquinone and nitro heterocyclic drugs (<a href="./references#CD004102-bbs2-0048" title="KubataB , KabututuZ , NozakiT , MundayC , FukuzumiS , OhkuboK , et al. A key role for old yellow enzyme in the metabolism of drugs by Tripanosoma cruzi. Journal of Experimental Medicine2002;196:1241-51. [DOI: 10.1084/jem.20020885]">Kubata 2002</a>). This reduction results in drug derived quinone intermediates as a source of free radicals which cause damage in organelles of parasitic protozoa. These reactions clarify the mechanism of action for both nifurtimox and benznidazole, with a well‐recognised clinical activity limited to acute and early chronic Trypanosoma infections, achieving a cure rate up to 100%; however, due to the unwanted side effects, treatment is frequently discontinued. </p> <p>Some promising results have been reported in the treatment of infected individuals in the chronic (indeterminate) phase of Chagas disease in trials carried out in Argentina and Brazil, where reduction of parasitaemia ranges from 58% to 95% (<a href="./references#CD004102-bbs2-0033" title="deAndradeA , ZickerF , deOliveiraR , AlmeidaS , LuquettiA , TravassosL , et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet1996;348(9039):1407-13. [DOI: 10.1016/s0140-6736(96)04128-1]">de Andrade 1996</a>; <a href="./references#CD004102-bbs2-0079" title="SosaS , SeguraE , RuizA , VelazquezE , PorcelB , YampotisC . Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. American Journal of Tropical Medicine and Hygiene1998;59:526-9. [DOI: 10.4269/ajtmh.1998.59.526]">Sosa 1998</a>; <a href="./references#CD004102-bbs2-0082" title="StoppaniA . The chemotherapy of Chagas disease [Quimioterapia de la enfermedad de Chagas]. Medicina1999;59(Suppl 2):147-65. [PMID: 10668258]">Stoppani 1999</a>). In addition, a Cochrane Review of 'Trypanocidal drugs for chronic asymptomatic <i>Trypanosoma cruzi</i> infection' showed that "nitro imidazole derivatives substantially and significantly modified parasite‐related outcomes compared to placebo and that other agents showed borderline or not significant effect" (<a href="./references#CD004102-bbs2-0089" title="VillarJ , VillarL , Marin-NetoJ , EbrahimS , YusufS . Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003463. [DOI: 10.1002/14651858.CD003463]">Villar 2002</a>); the review authors concluded that "Trypanocidal therapy, particularly nitro imidazole derivatives given to children or young adults with positive xenodiagnosis improve parasite‐related outcomes". That review has recently been updated: 13 studies were included (6 randomised controlled trials, 4 non‐randomised experiments, and 3 observational studies), and a total of 4229 participants received different trypanocidal drugs (benznidazole, nifurtimox, allopurinol and/or itraconazole). The review authors concluded that benznidazole and nifurtimox are still the treatments of choice for chronic asymptomatic patients. However, as most of the information about the efficacy of antitrypanocidal treatment comes from observational studies, consideration should be taken after advising the patient of the inconsistencies and uncertainties regarding the efficacy of trypanocidal therapy (<a href="./references#CD004102-bbs2-0090" title="VillarJC , PerezJG , CortesOL , RiarteA , PepperM , Marin-NetoJA , et al. Trypanocidal drugs for chronic symptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD003463. [DOI: 10.1002/14651858.CD003463.pub2]">Villar 2014</a>). </p> <p>Up to this point there has been no doubt that the pathophysiology of <i>T cruzi</i> in the acute phase has an important role in the aetiological treatment, whereas the participation of the parasite in the pathogenesis of chronic Chagas disease has been a question of debate for several decades. For the last 10 years, inhibitors of TcCYP51, an essential sterol for the survival of <i>T cruzi</i>, has been studied (miconazole, econazole, bis‐transole D0870, pozaconazole and E1224). Treatment efficacy in later stages of the disease remains questionable and controversial (<a href="./references#CD004102-bbs2-0024" title="AndradeJ , MarinJ , PaolaA , Vilas-BoasF , OliveiraG , BacalF , et al. I Latin American guidelines for the diagnosis and treatment of Chagas heart disease: executive summary. Arquivos Brasileiros de Cardiologia2011;96:434-42. [DOI: 10.1590/s0066-782x2011000600002]">Andrade 2011</a>; <a href="./references#CD004102-bbs2-0068" title="SalesP , MolinaI , FonsecaS , Sánchez-MontalváA , SalvadorF , Corrêa-OliveraR , et al. Experimental and clinical treatment of Chagas disease: a review. American Journal of Tropical Medicine and Hygiene2017;97(5):1289-303. [DOI: 10.4269/ajtmh.16-0761]">Sales 2017</a>). Furthermore, treatment effectiveness may be related to <i>T cruzi</i> strains, the susceptibility to different compounds or drugs, parasite genetic variability, geographical location, and the stage of Chagas disease when the treatment is used (<a href="./references#CD004102-bbs2-0068" title="SalesP , MolinaI , FonsecaS , Sánchez-MontalváA , SalvadorF , Corrêa-OliveraR , et al. Experimental and clinical treatment of Chagas disease: a review. American Journal of Tropical Medicine and Hygiene2017;97(5):1289-303. [DOI: 10.4269/ajtmh.16-0761]">Sales 2017</a>; <a href="./references#CD004102-bbs2-0087" title="UrbinaJ . Recent clinical trials for the etiological treatment of Chronic Chagas disease: advances, challenges and perspectives. Journal of Eukaryotic Microbiology2015;62(1):149-56. [DOI: 10.1111/jeu.12184]">Urbina 2015</a>). People with late‐stage, symptomatic Chagas disease are usually adults who are older than 25 years of age. Treatment in this phase of Chagas disease is usually limited to managing complications associated with the pathology found in the heart and digestive organs, and avoiding antiparasitics drugs because of potential adverse reactions. However, recent studies have shown that chronically ill patients treated with benznidazole had a significant reduction of blood antibodies compared with those in the placebo group. There is evidence that even if no cure was possible, fewer electrocardiographic abnormalities were found in the treatment group, which may be interpreted as due to the delay in tissue damage (<a href="./references#CD004102-bbs2-0052" title="MadyC , IanniB , deSouzaJ . Benznidazole and Chagas disease: can an old drug be the answer to an old problem?Expert Opinion on Investigational Drugs2008;17(10):1427-33. [DOI: 10.1517/13543784.17.10.1427]">Mady 2008</a>; <a href="./references#CD004102-bbs2-0055" title="MorettiE , CervettaL , BassoB , CastroI , SantamarinaN . Chronic Chagas' disease: effects of treatment on the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens [Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi]. Boletin Chileno de Parasitologia1998;53:3-9. [PMID: 9830716]">Moretti 1998</a>; <a href="./references#CD004102-bbs2-0078" title="SeguraM , MolinaE , BasombrioM . Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Memorias do Instituto Oswaldo Cruz1994;89:213-6. [DOI: 10.1590/s0074-02761994000200017]">Segura 1994</a>). </p> <p>Control programmes have focused on vector and transfusion transmission; it is now time that treatment and validated biomarker are assumed as part of these strategies. However, Coura has proposed that until the ideal drug for the treatment of late‐stage, symptomatic Chagas disease and CCC is developed, chagasic patients be treated with a combination of currently used drugs such as nifurtimox and benznidazole, along with potential drugs like allopurinol, and first‐, second‐, and third‐generation antifungal agents, all of which have different mechanisms of action, in order to boost the action of different compounds and avoid the development of parasite resistance (<a href="./references#CD004102-bbs2-0032" title="CouraJ . Present situation and new strategies for Chagas disease chemotherapy: a proposal. Memorias do Instituto Oswaldo Cruz2009;104(4):549-54. [DOI: 10.1590/s0074-02762009000400002]">Coura 2009</a>). </p> <p>The authors of a double‐blind, placebo‐controlled clinical trial conducted in 55 individuals from endemic areas of central Brazil concluded that at the used dose (900 mg/d), allopurinol was not effective to clear <i>T cruzi</i> from the peripheral blood of infected individuals (<a href="./references#CD004102-bbs2-0062" title="RassiA , LuquettiA , Rassi A Jr, RassiG , RassiS , Da SilvaIG , et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. American Journal of Tropical Medicine and Hygiene2007;76(1):58-61. [PMID: 17255230]">Rassi 2007</a>). </p> </section> <section id="CD004102-sec-0013"> <h3 class="title" id="CD004102-sec-0013">Why it is important to do this review</h3> <p>New drugs, such as the modified candidate cancer ones which have shown picomolar activity against cultured <i>T cruzi</i> and have been efficacious in a mouse model of acute Chagas disease, have been tested (<a href="./references#CD004102-bbs2-0047" title="KrausJ , VerlindeC , KarimiM , LepeshevaG , GelbM , BucknerF . Rational modification of a candidate cancer drug for use against Chagas disease. Journal of Medicinal Chemistry2009;52(6):1639-47. [DOI: 10.1021/jm801313t]">Kraus 2009</a>). </p> <p>Further studies need to be undertaken in both the acute and chronic phases of the disease, with strictly established cure criteria and specific diagnostic tests (e.g. polymerase chain reaction (PCR) methods) together with long‐term follow‐up of outcomes. </p> <p>Given that the potential of trypanocidal therapy to modify CCC had yet to be evaluated (<a href="./references#CD004102-bbs2-0086" title="UrbinaJ . Ergosterol biosynthesis and drug development for Chagas disease. Memorias do Instituto Oswaldo Cruz2009;104(Suppl 1):311-8. [DOI: 10.1590/s0074-02762009000900041]">Urbina 2009</a>), we performed this systematic review of the effects of treatment with nitrofuran or imidazole derivatives on clinically relevant outcomes in people with CCC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004102-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004102-sec-0014"></div> <p>To assess the benefits and harms of nitrofurans and trypanocidal drugs for treating late‐stage, symptomatic Chagas disease and CCC in terms of blood parasite reduction or clearance, mortality, adverse effects, and quality of life. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004102-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004102-sec-0015"></div> <section id="CD004102-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004102-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included trials reported as full text, abstract, and unpublished data in which participants were randomised individually to the administration of trypanocidal drugs (nitrofurans or benznidazole) versus placebo or no treatment for late‐stage, symptomatic Chagas disease and CCC. We did not include cluster‐randomised trials since participants were included as individuals, without sharing any characteristics, and because we were not certain that they belong to the same group (<a href="./references#CD004102-bbs2-0058" title="PermanG . Cluster clinical trials [Ensayos clínicos por conglomerados]. EVIDENCIA Actualizacion en la Practica Ambulatoria2017;20(1):22-5.">Perman 2017</a>). </p> </section> <section id="CD004102-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (between 25 and 65 years of age) with a definitive diagnosis of CCC defined clinically as the presence of either heart failure with or without specific dilated cardiomyopathy and/or tachyarrhythmia and/or heart block. A long 'incubation' period of usually more than 20 years prior to CCC was expected. </p> <p>In addition, serum antibodies to <i>T cruzi</i> demonstrated by at least two different validated tests (haemagglutination, indirect immunofluorescence, enzyme‐linked immunosorbent assay (ELISA)) (<a href="./references#CD004102-bbs2-0053" title="MonteónV , Guzman-BrachoC , Floriani-VerdugoJ , Ramos-EchavariaA , Velasco-CastrejónO , Reyes-LópezPA . Serological diagnosis of Chagas disease: self-sufficiency and interlaboratory concordance [Diagnóstico serológico de la enfermedad de Chagas: autosuficiencia y concordancia interlaboratorios]. Salud Publica de Mexico1995;37:232-5. [PMID: 7676350]">Monteón 1995</a>). We would also consider positive xenodiagnosis, positive blood culture or molecular biology assays as diagnostic tests if available, as well as pathological demonstration of tissue parasitism when biopsy or necropsy were done. </p> <p>We excluded studies in which participants had other diseases not related to late‐stage, symptomatic Chagas disease (diabetes, nephropathies, tuberculosis, HIV, uric acid, other infectious diseases), other cardiovascular diseases not related to CCC, or heart transplant. </p> <p>Participants who dropped out due to adverse effects, such as severe cutaneous reactions or peripheral polyneuropathy, or both, and the incidence of adverse events were reported. </p> <p>We included studies in which there was only a subset of interest if most participants met our inclusion criteria. We then carried out a sensitivity analysis that excluded studies with mixed populations. </p> </section> <section id="CD004102-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Since only the predominant effects of the active drug were included, we analysed the following two comparisons: </p> <p> <ol id="CD004102-list-0002"> <li> <p>benznidazole versus placebo or no treatment; and</p> </li> <li> <p>nifurtimox versus placebo or no treatment.</p> </li> </ol> </p> <p>Both drugs were orally administered at any dose specified for licensed trypanocidal drugs for at least 30 days. </p> </section> <section id="CD004102-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Reporting one or more of the outcomes listed above was not an inclusion criterion for the review. When a published report did not appear to report one of the above outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. Relevant trials that measured these outcomes but did not report the data at all, or not in a useable format, were included in the review as part of the narrative. </p> <section id="CD004102-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004102-list-0003"> <li> <p>Lowering or disappearance of parasitaemia or anti‐<i>T cruzi</i> antibodies, which was considered to have been achieved if one or more of the following were fulfilled. </p> <ul id="CD004102-list-0004"> <li> <p>Clearance or reduction of the mean antibody titres to <i>T cruzi</i> after treatment in comparison to the pretreatment results after a follow‐up period of at least 18 months. Mean anti‐<i>T cruzi</i> antibodies demonstrated by any of the following: haemagglutination, indirect immunofluorescence, and/or ELISA. </p> </li> <li> <p>Clearance of parasitaemia demonstrated by a negative xenodiagnosis, blood culture, and/or molecular biology assays 12 months after treatment. </p> </li> <li> <p>Pathological demonstration of tissue parasites (if a biopsy or necropsy was available).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD004102-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004102-list-0005"> <li> <p>Clinical improvement, defined as a reduction or disappearance of clinical signs of heart failure, rhythm and conduction defects on electrocardiogram (ECG). </p> </li> <li> <p>Quality of life, measured by a validated instrument, such as the 36‐item Short‐Form Health Survey (SF‐36) or the 12‐item Short‐Form Health Survey (SF‐12). </p> </li> <li> <p>Development of adverse effects such as severe cutaneous reactions, digestive intolerance, and/or peripheral polyneuropathy. </p> </li> </ul> </p> </section> </section> </section> <section id="CD004102-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004102-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials through a systematic search of the following bibliographic databases on 12 November 2019: </p> <p> <ul id="CD004102-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (via CRS Web);</p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 11 November 2019); </p> </li> <li> <p>Embase Classic and Embase (Ovid, 1947 to 11 November 2019);</p> </li> <li> <p>LILACS (in English) (Latin American and Caribbean Health Science Information database) (BIREME, 1982 to 12 November 2019). </p> </li> </ul> </p> <p>We searched the databases from their inception and imposed no restrictions on language of publication or publication status. We applied the sensitivity‐maximising randomised controlled trial (RCT) filter to MEDLINE and adaptations of it to Embase and LILACS (<a href="./references#CD004102-bbs2-0050" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). We did not perform a separate search for adverse effects of the interventions. </p> <p>The electronic searches were first run in 2004 (<a href="./appendices#CD004102-sec-0107">Appendix 2</a>), and then updated in March 2008 (<a href="./appendices#CD004102-sec-0108">Appendix 3</a>), March 2010 (<a href="./appendices#CD004102-sec-0109">Appendix 4</a>), and November 2019 (<a href="./appendices#CD004102-sec-0110">Appendix 5</a>). </p> </section> <section id="CD004102-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the following clinical trials registers on 3 December 2019:</p> <p> <ul id="CD004102-list-0007"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> </section> </section> <section id="CD004102-sec-0026"> <h3 class="title" id="CD004102-sec-0026">Data collection and analysis</h3> <section id="CD004102-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MV and MMG) independently screened the titles and abstracts of citations retrieved from the searches and identified potentially relevant papers. Lists of these papers were compared, with any disagreements resolved through discussion or by consulting a third review author (AGG) if required. We retrieved the full texts of all papers considered potentially relevant and examined them for inclusion or exclusion. The selection process is recorded in detail in <a href="#CD004102-fig-0001">Figure 1</a>, and <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a> and <a href="./references#CD004102-sec-0130" title="">Characteristics of excluded studies</a> were tabulated. </p> <div class="figure" id="CD004102-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>All articles were reviewed using a checklist in which the following information was identified. </p> <p> <ul id="CD004102-list-0008"> <li> <p>Method of random allocation of participants to the treatment group, and adequacy of concealment. </p> </li> <li> <p>Blinding of participants and physicians to the treatment group.</p> </li> <li> <p>Dose of trypanocidal drug, route of administration, and duration of treatment.</p> </li> <li> <p>Duration of follow‐up after treatment.</p> </li> <li> <p>Number and type of laboratory tests used in the diagnosis of participants and in the follow‐up. </p> </li> <li> <p>Cure criteria, clearance or disappearance of parasites, and reduction of parasite burden. </p> </li> <li> <p>Clinical data on cardiomyopathy.</p> </li> <li> <p>Sample size.</p> </li> <li> <p>Country in which the trial took place.</p> </li> <li> <p>Proportion of loss during follow‐up either as a result of withdrawals or dropouts in the treatment/placebo groups. </p> </li> <li> <p>Authors’ names, article title, publication type, source, language, year, and journal.</p> </li> </ul> </p> <p>The articles that did not fulfil all the relevant inclusion criteria were removed. In order to ensure thoroughness of the study selection process, we systematised the process as follows. We first applied terms related to the systematic review objectives and subsequently reviewed the titles and abstracts of the articles identified by the search. Articles were selected if the following MeSH terms were identified: </p> <p> <ul id="CD004102-list-0009"> <li> <p>those related to cardiomyopathy, dilated myocardiopathy, Chagas cardiomyopathy, and chronic Chagas disease; </p> </li> <li> <p>those related to nitroimidazole, nitrofurans, imidazole, nifurtimox, benznidazole, trypanocidal, itraconazole, and allopurinol; </p> </li> <li> <p>those related to study design, allocation, randomisation, and blinding process.</p> </li> </ul> </p> <p>The second step was to identify amongst those articles previously selected studies for inclusion and exclusion. For this purpose, a new set of MeSH terms were defined and classified as follows. </p> <section id="CD004102-sec-0028"> <h5 class="title">Excluded:</h5> <p> <ul id="CD004102-list-0010"> <li> <p>Other neglected tropical diseases such as African trypanosomiasis, leishmanial, malaria, <i>Trypanosoma evansi</i> , or <i>Trypanosoma brucei</i>. </p> </li> <li> <p>Other stages of Chagas disease (acute or acute indeterminate or gestational).</p> </li> <li> <p>Other diseases not related to Chagas disease (diabetes, nephropathies, tuberculosis, HIV, uric acid, other infectious diseases, cardiomyopathies not Chagas‐related, heart transplant). </p> </li> <li> <p>Other medicaments not imidazole or nitrofuran.</p> </li> <li> <p>Studies of a different nature (bibliometric, healthcare systems, experimental, reviews, case series, and brief reports). </p> </li> </ul> </p> </section> <section id="CD004102-sec-0029"> <h5 class="title">Included:</h5> <p> <ul id="CD004102-list-0011"> <li> <p>Randomised clinical trials</p> </li> </ul> </p> <p><i>Note:</i> The reviewed articles and experimental pharmacological studies (in vivo or in vitro) were used to update the Background. </p> <p>Those studies pre‐identified as included were further examined in full text. A checklist was developed for this purpose which was based on <i>GRADE Working Group</i> criteria (<a href="./references#CD004102-bbs2-0077" title="SchünemannH , BrożekJ , GuyattG , OxmanA . GRADE handbook for grading quality of evidence and strength of recommendations.. The GRADE Working Group.2013. [Available from guidelinedevelopment. org/handbook.]">Schunemann 2013</a>). </p> </section> </section> <section id="CD004102-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MV and MMG) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD004102-list-0012"> <li> <p>ID article information: author’s name, title of study, journal of publication, language and country in which the study took place. </p> </li> <li> <p>Methods: study design, total duration, number of study centres and locations, study settings, and date of study. </p> </li> <li> <p>Participants: adults meeting the eligibility criteria, N randomised and proportion of loss to follow‐up either as a result of withdrawals or dropouts in the treatment and placebo groups. </p> </li> <li> <p>Interventions: dose of trypanocidal drug, route of administration, and durations of treatment and follow‐up after treatment. Number and type of laboratory tests used in the diagnosis of participants and in the follow‐up. </p> </li> <li> <p>Outcomes: cure criteria, clearance or disappearance of parasites and reduction of parasite burden, and clinical data on cardiomyopathy. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Data were entered into the Review Manager 5 software package file and double‐checked against the data presented in the systematic review (<a href="./references#CD004102-bbs2-0064" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>Regarding the non‐RCTs, a further intentional search was undertaken in order to identify other studies that could have been published on the same topic, using the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We determined the purpose of the study, author name, location and settings, details of interventions (dose, type of medicaments, follow‐up period, etc.), the number of participants, baseline data, and date of publication (<a href="./references#CD004102-bbs2-0044" title="HigginsJ , AltmanD , GøtzscheP , JüniP , MoherD , OxmanA , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;18(343):d5928. [DOI: 10.1136/bmj.d5928 ]">Higgins 2011b</a>). </p> </section> <section id="CD004102-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MV and MMG) independently assessed the risk of bias for each study using the criteria described in the <i>Cochrane Handbook for Systematic Review of Interventions</i> (<a href="./references#CD004102-bbs2-0044" title="HigginsJ , AltmanD , GøtzscheP , JüniP , MoherD , OxmanA , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;18(343):d5928. [DOI: 10.1136/bmj.d5928 ]">Higgins 2011b</a>). Any disagreements were resolved by discussion or by involving a third review author (AGG) if necessary. We also contacted study authors for additional information or in order to obtain missing data. </p> <p>We assessed risk of bias according to the following domains.</p> <p> <ul id="CD004102-list-0013"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> </section> <section id="CD004102-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to express dichotomous data as risk ratios (RR) with 95% confidence intervals (CIs), or Peto odds ratios (OR) with 95% CIs if the sample size was very small (50 or fewer participants). Where continuous outcomes were reported using the same scale, we planned to calculate the mean difference (MD) with a 95% CI. For outcomes where data were reported using different scales, such as a different quality of life tools, we would use the standardised mean difference (SMD) with 95% CI. However, neither of the included studies reported continuous outcomes such as quality of life. </p> </section> <section id="CD004102-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We considered whether any unit of analysis issues could affect our data due to level of randomisation, multiple time points, or having more than a single pair‐wise comparison. </p> <p>For trials that had more than one intervention arm, we planned to combine groups to create a single pair‐wise comparison. Alternatively, we planned to reduce the sample size to control for multiple contributions from the same participants (splitting the 'shared' group into two or more groups). In the event, we included one study with three arms (benznidazole versus nifurtimox versus placebo). Since the two active treatments belonged to different comparisons, the placebo arm could be included for both groups without there being a unit of analysis problem. </p> </section> <section id="CD004102-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We analysed sources of missing data (randomly assigned participants, intention‐to‐treat and as‐treated and per‐protocol populations); additionally, we evaluated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals) and used imputation methods such as the last observation carried forward. </p> <p>If a trial did not report the mean and standard deviation (SD) for the outcomes, and the authors of the trial did not share this information, we would impute values by estimating the mean and SD from the median, the range, and the sample size of the trial (<a href="./references#CD004102-bbs2-0045" title="HozoS , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5(13):1-10. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). In order to calculate a missing SD from other reported data in the trials, we would use the 95% CI in the Review Manager 5. However, this was not required. </p> <p>We planned to carry out sensitivity analysis to evaluate the imputation impact on meta‐analysis, but this was not required. </p> </section> <section id="CD004102-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the case of substantial clinical or methodological heterogeneity, we would not combine results as a pooled effect. We planned to visually inspect forest plots and standard Chi<sup>2</sup> test with a level of significance of P = 0.1 to help identify heterogeneity or inconsistencies (<a href="./references#CD004102-bbs2-0044" title="HigginsJ , AltmanD , GøtzscheP , JüniP , MoherD , OxmanA , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;18(343):d5928. [DOI: 10.1136/bmj.d5928 ]">Higgins 2011b</a>). Since this test has low power, we also planned to use the I<sup>2</sup> statistic to quantify inconsistencies across trials, thereby assessing the impact of heterogeneity on the meta‐analysis (<a href="./references#CD004102-bbs2-0041" title="HigginsJ , ThompsonS . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD004102-bbs2-0042" title="HigginsJ , ThompsonS , DeeksJ , AltmanD . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>). We planned to use subgroup characteristics as well as an individual trial assessment to determine the possible reasons for heterogeneity. In the event, we were unable to pool more than one study for any outcome. </p> <p>We planned to use a fixed‐effect model, unless substantial heterogeneity existed based on I<sup>2</sup> &gt; 50%. </p> </section> <section id="CD004102-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we been able to include several studies investigating the same outcome (10 or more), we would have used funnel plots to assess small‐study effects. Any identified asymmetry could have been due to the heterogeneity of effects with respect to 1) trial size or 2) poor methodological design (and therefore bias of small trials) and 3) publication bias (<a href="./references#CD004102-bbs2-0080" title="SterneJ , GavaghanD , EggerM . Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology2000;53:1119–29. [DOI: 10.1016/s0895-4356(00)00242-0]">Sterne 2000</a>). We would have interpreted results carefully (<a href="./references#CD004102-bbs2-0081" title="SterneJ , MatthiasE , SmithG . Investigating and dealing with publication and other biases in meta-analysis. BMJ2001;323:189-208. [DOI: 10.1136/bmj.323.7304.101 ]">Sterne 2001</a>). </p> </section> <section id="CD004102-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Had we identified sufficient studies for inclusion in the review with outcomes suitable for meta‐analysis, we would have analysed them as follows. </p> <p>We planned to express dichotomous data as RR with 95% CIs, or Peto OR with 95% CIs if the sample size was very small (50 or fewer participants). The percentage of events in the placebo group was less than 10%, and the number of included studies was small. We also planned to express continuous data as the mean and SD difference from baseline to follow‐up for each comparison group. Where SD differences were not reported in source papers, we would make allowance for within‐participant correlation from baseline to follow‐up measurements by using the correlation coefficient between the two (<a href="./references#CD004102-bbs2-0030" title="Cochrane Heart Group. Preferred method for handling continuous variables. www.heart.cochrane.org/Files/Handling%20continuous%20variables.pdf (accessed June 2005).">Cochrane Heart Group</a>; <a href="./references#CD004102-bbs2-0035" title="FollmanD , ElliotP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45:769-73. [DOI: 10.1016/0895-4356(92)90054-q]">Follman 1992</a>). We would have calculated the difference in means and 95% CI for each study. </p> </section> <section id="CD004102-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct the following subgroup analyses to investigate heterogeneity.</p> <p> <ul id="CD004102-list-0014"> <li> <p>Dose of treatment.</p> </li> <li> <p>Treatment compliance.</p> </li> </ul> </p> </section> <section id="CD004102-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses to explore effect sizes by restricting the analysis to the following factors. </p> <p> <ul id="CD004102-list-0015"> <li> <p>Effect of risk of bias in included studies.</p> </li> <li> <p>Time of interventions administration.</p> </li> </ul> </p> <p>We also planned to test the robustness of the results by repeating the analysis using different statistical models (fixed‐effect and random‐effects models) to identify any inconsistencies in the results. </p> <p>As we only included two studies, it was not possible to carry out any sensitivity or subgroup analyses. </p> </section> <section id="CD004102-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the quality of the evidence. The following criteria were used: limitations in the design and implementation, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, and high probability of publication bias. We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004102-bbs2-0043" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), employing GRADEpro GDT software package (<a href="./references#CD004102-bbs2-0038" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed prior to 10 December 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). A separate summary table of the outcomes is presented for each comparison. Two review authors (MV and MMG) independently assessed the level of the evidence. Any disagreements were resolved by discussion or by consulting a third review author (AGG). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004102-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004102-sec-0041"></div> <section id="CD004102-sec-0042"> <h3 class="title">Description of studies</h3> <p>For a detailed description of the trials, see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>, <a href="./references#CD004102-sec-0130" title="">Characteristics of excluded studies</a>, and <a href="./references#CD004102-sec-0131" title="">Characteristics of ongoing studies</a>. </p> <section id="CD004102-sec-0043"> <h4 class="title">Results of the search</h4> <p>In the 2010 review update, we identified the ongoing study (BENEFIT) (<a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>), a multicentre, randomised, double‐blind, placebo‐controlled clinical trial in which 1431 participants with CCC were randomly assigned to benznidazole 300 mg/day per 40 to 80 days and 1423 participants to placebo; for this update, the trial had finished, and we included its findings in the review. </p> <p>In the current update, 989 new records were identified after de‐duplication. Of 21 articles retrieved in full text, we excluded 20 (9 observational studies; 2 non‐RCTs; 6 studies probing the efficacy of reducing <i>T cruzi</i> antibodies; and 3 studies concerned with other aspects of Chagas disease), and identified 1 new RCT as ongoing <a href="./references#CD004102-bbs2-0023" title="NCT03191162. Evaluation of different benznidazole regimens for the treatment of chronic Chagas disease (MULTIBENZ). clinicaltrials.gov/ct2/show/NCT03191162 (first received 19 June 2017). ">NCT03191162</a>. For further details, see <a href="#CD004102-fig-0001">Figure 1</a>. </p> </section> <section id="CD004102-sec-0044"> <h4 class="title">Included studies</h4> <p>For details of the included studies, see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>. </p> <section id="CD004102-sec-0045"> <h5 class="title">Source of data</h5> <p>We obtained data from the published literature and attempted to contact study authors for additional information or in order to obtain missing data (<a href="./appendices#CD004102-sec-0111">Appendix 6</a>). </p> </section> <section id="CD004102-sec-0046"> <h5 class="title">Comparisons</h5> <p>In the two included studies, we identified only two types of intervention: benznidazole or nifurtimox versus placebo (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>; <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>). <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> compared benznidazole with placebo, and <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> compared benznidazole and nifurtimox with placebo. </p> </section> <section id="CD004102-sec-0047"> <h5 class="title">Overview of trial populations</h5> <p>The included studies involved a total of 2940 participants. <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> randomly assigned each participant to one of two study groups: 1431 in the benznidazole group (300 mg per day, and a variable duration of therapy based on participant weight) and 1423 in the placebo group for 60 days, with follow‐up at one, two, and five years (see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> randomly assigned 77 participants to one of three study groups: 26 in the benznidazole group (5 mg/kg/day every 12 hours); 27 in the nifurtimox group (5 mg/kg/day every 12 hours); and 24 in the placebo group, for 30 days of treatment for all groups. Outcomes were assessed at 1, 2, 3, and 12 months after the end of treatment. For details, see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>. </p> <p>Description of interventions related frequency and total dose/day are detailed in <a href="./appendices#CD004102-sec-0112">Appendix 7</a>; As well as, duration of intervention, and other baseline characteristics are showed in <a href="./appendices#CD004102-sec-0113">Appendix 8</a> and <a href="./appendices#CD004102-sec-0114">Appendix 9</a>. </p> </section> <section id="CD004102-sec-0048"> <h5 class="title">Trial design</h5> <p>The two included studies were parallel comparisons with individual randomisation (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>; <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>). </p> </section> <section id="CD004102-sec-0049"> <h5 class="title">Settings</h5> <p>In both trials, the interventions were carried out in outpatient settings (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>; <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>). </p> </section> <section id="CD004102-sec-0050"> <h5 class="title">Participants</h5> <p>Both trials included participants from low‐ to middle‐income countries (Brazil, Argentina, Bolivia, Colombia, and El Salvador) (see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>). </p> </section> <section id="CD004102-sec-0051"> <h5 class="title">Diagnosis</h5> <p>In the case of Morillo’s trial (BENEFIT) (<a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>), at least two positive serological tests (indirect immunofluorescence, indirect haemagglutination, or ELISA) for chronic Chagas disease in any combination were recorded. In <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>, all participants had immunofluorescence and complement fixation reactions positive for <i>T cruzi</i> antibodies, and at least two xenodiagnoses were positive of the three performed before treatment. </p> </section> <section id="CD004102-sec-0052"> <h5 class="title">Outcome</h5> <p>In <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>, the primary outcome was the composite of death; resuscitated cardiac arrest; sustained ventricular tachycardia; insertion of a pacemaker or cardiac defibrillator; cardiac transplantation; and development of new heart failure, stroke, or systemic or pulmonary thromboembolic events. The secondary outcome was the response to treatment on the basis of the results on PCR assay to detect circulating <i>T cruzi</i> kinetoplast DNA (kDNA) by means of an internationally validated method (<a href="./references#CD004102-bbs2-0071" title="SchijmanA , BisioM , OrellanaL , SuedM , DuffyT , MejiaA , et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLOS Neglected Tropical Diseases2011;5(1):e931. [DOI: 10.1371/journal.pntd.0000931]">Schijman 2011</a>). </p> <p>In <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>, the primary outcome was the clearance of the blood parasite by xenodiagnosis and adverse effects (digestive intolerance and neuropsychiatric manifestations, cutaneous rash). See <a href="./appendices#CD004102-sec-0115">Appendix 10</a> for more detail of trials endpoint and <a href="./appendices#CD004102-sec-0116">Appendix 11</a> for the definitions of endpoint measurement. </p> </section> </section> <section id="CD004102-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We reviewed 21 full‐text articles and excluded 20 for the following reasons: observational studies (9 studies), non‐RCTs (2 studies), efficacy to reduce <i>T cruzi</i> antibodies (6 studies), and other aspects of Chagas disease (3 studies) (see <a href="./references#CD004102-sec-0130" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD004102-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>In <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>, the participants were recruited from two places in Minais Gerais, Brazil. All of them were chronic chagasic patients with an independently established diagnosis which included seropositivity, xenodiagnosis, and clinical assessments including ECG and esophagram. The participants were randomly allocated to three groups: placebo, benznidazole, and nifurtimox. The method of randomisation was not reported. Participants and physicians were blind to the treatment group. Sixty‐four participants completed the study and were evaluated at 1, 2, 3, and 12 months after treatment, with 3 xenodiagnostic tests at 15 days’ interval. Additionally, participants underwent two serological assays. Of the 77 participants included in the study, 83% completed the treatment. Confounding variables such as sex and age were evenly distributed between groups. The sample size was clearly too small to provide adequate power to detect clinically important differences in the outcomes (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>). </p> <p>The BENEFIT study is a multicentric (Argentina, Bolivia, Brazil, Colombia, and El Salvador), randomised, double‐blind controlled trial involving participants with Chagas cardiomyopathy. Individuals were randomly assigned to either placebo or benznidazole with a randomisation ratio of 1:1 using a random‐block system. The blinding method was not reported. Participants were evaluated at 11 and 21 days and 2 months after initiation of treatment, and were followed up at the 6‐month mark, and then annually until a minimum of 4 years and a maximum of 7 years. All participants completed the full course of treatment and were available at the 1‐year follow‐up; at 2 years, 99% were available, and at 7 years, 99.5% were available (<a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>). </p> <p>For details, see <a href="./references#CD004102-sec-0129" title="">Characteristics of included studies</a>. For judgement of the risk of bias for each study and for studies overall, see <a href="#CD004102-fig-0002">Figure 2</a> and <a href="#CD004102-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004102-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004102-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004102-sec-0055"> <h4 class="title">Allocation</h4> <p>Only <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> detailed the method used for random sequence generation and allocation concealment, therefore we considered <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> to be at unclear risk of selection bias. </p> </section> <section id="CD004102-sec-0056"> <h4 class="title">Blinding</h4> <p>We assessed <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> as at unclear risk of bias as minimal information is provided regarding the blinding of physicians in charge of examining the participants. <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> mentions that allocation, evaluation, and statistical analysis will be blinded; however, as there is no comprehensive explanation of the process, we judged the trial to be at unclear risk of bias. </p> </section> <section id="CD004102-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> reported clearance of parasitaemia, and 96% of participants in the placebo group remained positive after treatment. Participants in the nifurtimox group exhibited a higher rate of withdrawals (29.6%), followed by the benznidazole group (11.5%). Most participants in the placebo group continued until the end of the study (attrition rate 8.3%). However, information regarding exclusion or attrition is limited, therefore we assessed this trial as at unclear risk of attrition bias. </p> <p><a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> reported a reduction of anti‐<i>T cruzi</i> antibodies in 66% of participants; of these, the PCR conversion rate was 66.2% in the benznidazole group and 33.5% in the placebo group. At the end of treatment, a higher rate of withdrawal was observed in the benznidazole group than in the placebo group (18% versus 12%); at two years’ follow‐up, this was higher in the placebo group than in the benznidazole group (7% versus 5%). We judged this trial as at unclear risk of attrition bias due to insufficient information on the reduction in PCR tests. </p> </section> <section id="CD004102-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Both included trials reported outcomes in insufficient detail, therefore they are assessed as at unclear risk of reporting bias. </p> </section> <section id="CD004102-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We detected no other sources of bias in the two included trials.</p> </section> </section> <section id="CD004102-sec-0060"> <h3 class="title" id="CD004102-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD004102-tbl-0001"><b>Summary of findings 1</b> Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</a>; <a href="./full#CD004102-tbl-0002"><b>Summary of findings 2</b> Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</a> </p> <section id="CD004102-sec-0061"> <h4 class="title">Benznidazole versus placebo</h4> <p>See <a href="./full#CD004102-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD004102-sec-0062"> <h5 class="title">Primary outcomes</h5> <section id="CD004102-sec-0063"> <h6 class="title">Lowering or disappearance of parasitaemia</h6> <section id="CD004102-sec-0064"> <p><b>Clearance or reduction of anti‐T cruzi antibodies</b></p> <p>Only <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> reported antibody clearance after five years of follow‐up: </p> <p> <ul id="CD004102-list-0016"> <li> <p>for benznidazole at 12 months, the risk ratio (RR) was 1.91 (95% confidence interval (CI) 1.64 to 2.21; P &lt; 0.001; 1 trial; 1896 participants; low quality of the evidence in favour of intervention; <a href="./references#CD004102-fig-0004" title="">Analysis 1.1</a>); </p> </li> <li> <p>for benznidazole at 2 years, the RR was 1.44 (95% CI 1.29 to 1.60; P &lt; 0.001; 1 trial; 1896 participants; low quality of the evidence in favour of intervention; <a href="./references#CD004102-fig-0004" title="">Analysis 1.1</a>); </p> </li> <li> <p>for benznidazole at 5 years, the RR was 1.25 (95% CI 1.14 to 1.37; P &lt; 0.001; 1 trial; 1896 participants; low quality of the evidence in favour of intervention; <a href="./references#CD004102-fig-0004" title="">Analysis 1.1</a>). </p> </li> </ul> </p> </section> <section id="CD004102-sec-0065"> <p><b>Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays</b></p> <p>One trial reported applying xenodiagnosis for this comparison (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>). The Peto odds ratio (OR) was 31.66 (95% CI 10.56 to 94.97; P &lt; 0.001; 1 trial; 50 participants; very low quality of the evidence in favour of benznidazole; <a href="./references#CD004102-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD004102-sec-0066"> <p><b>Lowering or disappearance of parasitaemia or anti‐<i>T cruzi</i> antibodies.</b></p> <p>None of the included studies reported the disappearance of parasitaemia by pathological demonstration. </p> </section> </section> </section> <section id="CD004102-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD004102-sec-0068"> <h6 class="title">Clinical improvement</h6> <p>Only <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> reported cardiovascular outcomes: </p> <p> <ul id="CD004102-list-0017"> <li> <p>for the risk of heart failure, the RR was 0.89 (95% CI 0.69 to 1.14; P = 0.35; 1 trial; 2854 participants; low quality of the evidence indicates that compared to placebo, the used of benznidazole may make little to no differences; Analysis 1.3); </p> </li> <li> <p>for sustained ventricular tachycardia, the RR was 0.80 (95% CI 0.51 to 1.26; P = 0.33; 1 trial; 2854 participants; low quality of the evidence in favour of benznidazole; <a href="./references#CD004102-fig-0006" title="">Analysis 1.3</a>). </p> </li> </ul> </p> </section> <section id="CD004102-sec-0069"> <h6 class="title">Quality of life</h6> <p>Neither trial evaluated this outcome.</p> </section> <section id="CD004102-sec-0070"> <h6 class="title">Development of adverse effects</h6> <p>The most frequent adverse effects were cutaneous rashes, gastrointestinal symptoms, and peripheral polyneuropathy. In <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>, the RR to develop any adverse events was 2.52 (95% CI 2.09 to 3.03; P &lt; 0.01; 1 trial; 2854 participants; moderate quality of the evidence in favour of placebo; <a href="./references#CD004102-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD004102-sec-0071"> <h5 class="title">Subgroup analyses</h5> <p>Due to an insufficient number of studies we did not perform subgroup analyses.</p> </section> <section id="CD004102-sec-0072"> <h5 class="title">Sensitivity analyses</h5> <p>Due to an insufficient number of studies we did not perform sensitivity analyses.</p> </section> </section> <section id="CD004102-sec-0073"> <h4 class="title">Nifurtimox versus placebo</h4> <p>See <a href="./full#CD004102-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD004102-sec-0074"> <h5 class="title">Primary outcomes</h5> <section id="CD004102-sec-0075"> <h6 class="title">Lowering or disappearance of parasitaemia</h6> <section id="CD004102-sec-0076"> <p><b>Clearance or reduction of anti‐T cruzi antibodies</b></p> <p>Only <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> reported antibody clearance with the administration of nifurtimox compared to placebo for 30 days, with an RR of 16.89 (95% CI 2.44 to 116.85; P = 0.004; 1 trial; 51 participants; very low quality of the evidence in favour of nifurtimox; <a href="./references#CD004102-fig-0008" title="">Analysis 2.1</a>). </p> </section> <section id="CD004102-sec-0077"> <p><b>Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays</b></p> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> did not evaluate this outcome. </p> </section> <section id="CD004102-sec-0078"> <p><b>Disappearance of parasites in the tissues</b></p> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> did not evaluate the disappearance of parasitaemia by pathological demonstration. </p> </section> </section> </section> <section id="CD004102-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD004102-sec-0080"> <h6 class="title">Clinical improvement</h6> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> did not evaluate this outcome. </p> </section> <section id="CD004102-sec-0081"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> did not evaluate this outcome. </p> </section> <section id="CD004102-sec-0082"> <h6 class="title">Development of adverse effects</h6> <p>The development of adverse effects such as gastrointestinal intolerance, paraesthesia, and other nervous system issues was more frequent in the intervention group. Details on adverse effects can be found in the <a href="./appendices#CD004102-sec-0117">Appendix 12</a>; <a href="./appendices#CD004102-sec-0118">Appendix 13</a>; <a href="./appendices#CD004102-sec-0119">Appendix 14</a>. </p> </section> </section> <section id="CD004102-sec-0083"> <h5 class="title">Subgroup analyses</h5> <p>Due to an insufficient number of studies we did not perform subgroup analyses.</p> </section> <section id="CD004102-sec-0084"> <h5 class="title">Sensitivity analyses</h5> <p>Due to an insufficient number of studies we did not perform sensitivity analyses.</p> </section> <section id="CD004102-sec-0085"> <h5 class="title">Assessment of reporting bias</h5> <p>Due to the limited number of trials for any given outcome we did not draw funnel plots.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004102-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004102-sec-0086"></div> <section id="CD004102-sec-0087"> <h3 class="title" id="CD004102-sec-0087">Summary of main results</h3> <p>We included two studies in this update. <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> compared treatment with nifurtimox or benznidazole with placebo for the clearance of parasitaemia. Infection was assessed using indirect immunofluorescence in a screening assay followed by positive complement fixation as well as confirmatory parasitologic assay (at least two out of the three positive xenodiagnosis results). Twenty‐six participants were randomly assigned to benznidazole 5 mg/kg/day, 27 to nifurtimox 5 mg/kg/day, and 24 to placebo for 30 days. <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a> included 2854 participants with late‐stage, symptomatic Chagas disease and CCC: 1431 participants were randomly assigned to benznidazole 300 mg/day for 40 to 80 days, and 1423 to placebo. We also identified one ongoing study (<a href="./references#CD004102-bbs2-0023" title="NCT03191162. Evaluation of different benznidazole regimens for the treatment of chronic Chagas disease (MULTIBENZ). clinicaltrials.gov/ct2/show/NCT03191162 (first received 19 June 2017). ">NCT03191162</a>). </p> <p><b>Benznidazole compared to placebo</b> </p> <p>Low quality of the evidence from the BENEFIT study trial, <a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>, suggests there may be a benefit of benznidazole when compared to placebo for clearance or reduction of antibody titres at 12 months (RR 1.91, 95% CI 1.64 to 2.21), 2 years (RR 1.44, 95% CI 1.29 to 1.60), and 5 years (RR 1.25, 95% CI 1.14 to 1.37). This shows that the effect of the intervention declines over time as a result of the natural reduction of the antibodies titres as an individual immune response rather than as the effect of the imidazolic treatment. </p> <p>Due to very limited evidence, we are uncertain about the effects of benznidazole on the clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays. </p> <p>Low quality of the evidence suggests that benznidazole may make little to no difference for the risk of heart failure and ventricular tachycardia when compared to placebo. </p> <p>Moderate quality of the evidence shows that adverse events increase with benznidazole when compared to placebo. Adverse effects were observed in 23.9% of patients in the Benznidazole group compared to 9.5% in the placebo group. The most frequent adverse effects were: cutaneous rash, gastrointestinal symptoms, and peripheral polyneuropathy. </p> <p>No data were available for the outcomes pathological demonstration of tissue parasites and quality of life. </p> <p><b>Nifurtimox compared to placebo</b> </p> <p>The only outcome with data available for this comparison was clearance or reduction of antibody titres in <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>, with an RR of 16.89 (95% CI 2.44 to 116.85; P = 0.004; 1 trial; 51 participants). Even though the estimated RR is large in favour of nifurtimox efficacy, we are uncertain about the effect due to very limited evidence to establish the effectiveness of nifurtimox for the treatment of late‐stage, symptomatic Chagas disease and CCC. </p> <p>Regarding adverse events, <a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a> mentioned in a general manner that nifurtimox caused more intense adverse events than benznidazole, without any quantification. </p> </section> <section id="CD004102-sec-0088"> <h3 class="title" id="CD004102-sec-0088">Overall completeness and applicability of evidence</h3> <p>This review included only two randomised clinical trials. The purpose of both studies was to clarify the therapeutic role of the nitrofuran and imidazole drugs in late‐stage, symptomatic Chagas disease and CCC; however, it was not possible to conduct a meta‐analysis due to the small number of trials identified. Furthermore, due to the low level of certainty, especially in relation to the effect of nifurtimox compared to placebo, since only 51 participants were included, only one study was reviewed, and there is a high risk of bias. Consequently, for this outcome, it remains uncertain whether the use of this type of drugs in the chronic phase has no effect once Chagas disease has provoked organ damage, and is pending further corroboration that may come from the currently ongoing study. </p> </section> <section id="CD004102-sec-0089"> <h3 class="title" id="CD004102-sec-0089">Quality of the evidence</h3> <p>It is important to note that there is a gap of almost 20 years between the two RCTs included in this review. This is significant because the burden and costs of the chronic diseases were finally accepted by health authorities in most Latin American countries. With this in mind, the quality of evidence of the first RCT may be questionable, since sources of financing were scarce, and most studies were conducted with limited resources. Consequently, selection bias may have been introduced; random allocation and concealment are not explained; attrition bias regarding adverse events was introduced; and outcome data are incomplete (<a href="./references#CD004102-bbs2-0001" title="CouraJR , De AbreuL , PercyH , WillcoxF , PetanaW . A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chagas disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical1997;30:139-44. [DOI: 10.1590/s0037-86821997000200009]">Coura 1997</a>). The second study is a multicentric RCT with a sample of 2854 participants with late‐stage, symptomatic Chagas disease and CCC, from five endemic countries, with a long follow‐up (up to seven years). Random allocation and concealment were detailed; adverse events were fully informed; and attrition bias may have occurred in relation to the PCR test since only 66% of participants were tested (<a href="./references#CD004102-bbs2-0002" title="MorilloC , Marin-NetoJ , AvezumA , Sosa-EstaniS , RassiA , RosasF , et al, BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New England Journal of Medicine2015;373:1295-306. [DOI: 10.1056/NEJMoa1507574]">Morillo 2015</a>). We judged that this study has a low or unclear risk of bias. </p> </section> <section id="CD004102-sec-0090"> <h3 class="title" id="CD004102-sec-0090">Potential biases in the review process</h3> <p>We followed standard Cochrane methodology in order to avoid duplication and publication bias; there were no restrictions regarding the language or date of publication. The review was undertaken by three review authors working independently. We attempted to contact study authors in order to obtain missing data; however, one of the trials was published almost 20 years ago. Since Chagas disease is a neglected tropical disease, with little interest from the authorities, limited studies are conducted in relation to the efficacy of parasitological cure in the late‐stage of the disease (<a href="./references#CD004102-bbs2-0084" title="TarletonRL , GürtlerRE , UrbinaJA , RamseyJ , ViottiR . Chagas disease and the London declaration on neglected tropical diseases. PLOS Neglected Tropical Diseases2014;10(8):e3219. [DOI: 10.1371/journal.pntd.0003219]">Tarleton 2014</a>). </p> </section> <section id="CD004102-sec-0091"> <h3 class="title" id="CD004102-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>Human infection with <i>T cruzi</i> induces an immune response in most human hosts, but a chronic indolent infection is common. A proportion of the infected people develop late‐stage, symptomatic Chagas disease with two main clinical patterns: heart disease or dilated gastrointestinal 'mega' syndromes. Chronic chagasic cardiomyopathy may produce a progressive heart disease characterised by rhythm and conduction disorders with or without dilated cardiomyopathy. Both high morbidity and mortality of people with these manifestations of Chagas disease is common. </p> <p>Interventions to treat Chagas disease were initiated shortly after its description early in the 20th century. However, they were unsuccessful for 50 years. In 1962, the first useful drug treatment was found using animal models – a nitrofuran derivative marketed as Nifurtimox – and was shortly followed by the imidazole drug benznidazole, both of which have become the cornerstone of treatment of American trypanosomiasis. Good results have been found in acute infections, with the absence of parasitaemia in most treated patients and remission of serologic response. These drugs are now used in recently infected children, in cases of laboratory needle stick injuries resulting in acute infection, as well as in iatrogenic infection through contaminated blood products (<a href="./references#CD004102-bbs2-0066" title="Rodriguez-CouraJ , CastroS . A critical review on Chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz2002;97:3-24. [DOI: 10.1590/s0074-02762002000100001]">Rodriguez‐Coura 2002</a>; <a href="./references#CD004102-bbs2-0082" title="StoppaniA . The chemotherapy of Chagas disease [Quimioterapia de la enfermedad de Chagas]. Medicina1999;59(Suppl 2):147-65. [PMID: 10668258]">Stoppani 1999</a>; <a href="./references#CD004102-bbs2-0085" title="UrbinaJ . Parasitological cure of Chagas disease: is it possible? Is it relevant?Memorias do Instituto Oswaldo Cruz1999;94(Suppl 1):349-55. [DOI: 10.1590/s0074-02761999000700068]">Urbina 1999</a>). </p> <p>In questioning the efficacy of nifurtimox and benznidazole in the treatment of late‐stage, symptomatic Chagas disease and CCC, we found only two controlled clinical trials. We did not find strong evidence that standard treatment with either nifurtimox or benznidazole in individuals with late‐stage <i>T cruzi</i> infection is beneficial. </p> <p>A major problem in conducting trials and interpreting long‐term prognostic studies is the issue of criteria to define cure. For example, some studies have shown a significant reduction of blood antibodies and fewer ECG abnormalities in chronically infected patients treated with benznidazole compared to a placebo group, and interpreted this as an indication of a delay in tissue damage (<a href="./references#CD004102-bbs2-0055" title="MorettiE , CervettaL , BassoB , CastroI , SantamarinaN . Chronic Chagas' disease: effects of treatment on the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens [Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi]. Boletin Chileno de Parasitologia1998;53:3-9. [PMID: 9830716]">Moretti 1998</a>; <a href="./references#CD004102-bbs2-0078" title="SeguraM , MolinaE , BasombrioM . Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Memorias do Instituto Oswaldo Cruz1994;89:213-6. [DOI: 10.1590/s0074-02761994000200017]">Segura 1994</a>; <a href="./references#CD004102-bbs2-0021" title="ViottiR , ViglianoC , ArmentiH , SeguraE . Treatment of chronic Chagas' disease with benznidazole: clinical and serological evolution of patients with long-term follow-up. American Heart Journal1994;127:151-62. [DOI: 10.1016/0002-8703(94)90521-5]">Viotti 1994</a>). A clinical criteria for cure requires the disappearance of parasitaemia, but this is not easy to demonstrate in chronic cases, with the sensitivity of haemoculture or xenodiagnosis being no more than 50% at best. Inclusion of this criterion is clearly insufficient to determine the efficacy of drug treatment, and, perhaps not surprisingly, most papers have failed to demonstrate any reduction in parasitaemia (<a href="./references#CD004102-bbs2-0031" title="ContijoE , GalvãoL , Eloi-SantosS . Chagas disease: criteria of cure and prognosis. Memorias do Instituto Oswaldo Cruz1999;94(Suppl 1):357-62. [DOI: 10.1590/S0074-02761999000700069]">Contijo 1999</a>; <a href="./references#CD004102-bbs2-0085" title="UrbinaJ . Parasitological cure of Chagas disease: is it possible? Is it relevant?Memorias do Instituto Oswaldo Cruz1999;94(Suppl 1):349-55. [DOI: 10.1590/s0074-02761999000700068]">Urbina 1999</a>). </p> <p>The diagnosis of Chagas disease has limitations, mainly due to the great complexity of the factors involved in it, as well as the low sensitivity of parasitological techniques and the low specificity of immunological tests, such as those used in the two studies included in this review. Circulating antibodies against <i>T cruzi</i> is a diagnostic hallmark of chronic infection. The disappearance of antibodies has been used as a clinical cure criterion in acute disease, but does not occur in the chronic Chagas disease. The current established criteria to define cure in CCC may be insufficient and outdated. New developments in molecular biology have further challenged the existing clinical cure criteria. Parasite DNA can now be clearly demonstrated in several tissues, thereby reinforcing the notion of parasite persistence (despite apparent clinical cure) and its possible role as an inducer of an immune response. Changes in <i>Trypanosoma cruzi</i>‐specific immune response after treatment with benznidazole have been proven by Laucella and colleagues (<a href="./references#CD004102-bbs2-0049" title="LaucellaS , MazliahD , BertocchiG , AlvarezM , CooleyG , ViottiR , et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clinical Infectious Diseases2009;49(11):1675-84. [DOI: 10.1086/648072]">Laucella 2009</a>), who found a significant decline of peripheral interferon (IFN) gamma‐producing T cells specific for <i>T cruzi</i> as early as 12 months after benznidazole treatment and which became undetectable in a substantial proportion of treated participants. Finally, further RCTs are needed that consider the application of immunomics, which combines serology with proteomics. This would help to discover genes and molecules related to the susceptibility and immunity of <i>T cruzi</i> infection, allowing the creation of an adequate diagnosis of the disease, elucidating new targets and therapies, and, why not, making possible the creation of a vaccine against Chagas disease (<a href="./references#CD004102-bbs2-0051" title="López-MonteonA , DumonteilE , Ramos-LigonioA . More than a hundred years in the search for an accurate diagnosis for Chagas disease: current panorama and expectations. In: Rodriguez-MoralesAJ , editors(s). Current Topics in Neglected Tropical Diseases. IntechOpen, 2019:4-14. [DOI: 10.5772/intechopen.86567]">Lopez‐Monteon 2019</a>). </p> <p>Both nifurtimox and benznidazole are linked to adverse reactions (peripheral neuropathy, skin disorders, and other health problems) in a relatively high proportion of users. This indicates the need for safer and effective drugs for late‐stage, symptomatic Chagas disease and CCC, where treatment is likely to be long term. On balance, the limited findings of this review cast doubt on the efficacy of treatment for CCC with either nifurtimox or benznidazole, but do provide modest evidence of potential harm from adverse effects. </p> <p>We also identified non‐RCTs as follows.</p> <p>A study was conducted in Brazil with 17 patients who had completed full treatment with antitrypanosomal drugs (nitrofurans or nitroimidazole 10 mg/kg/day) and were age‐ and sex‐matched with patients from a cohort study of chronic chagasic cardiomyopathy patients, all of whom showed immunological and/or serological assay evidence of <i>T cruzi</i>. The aim was to determine whether serological or immunological cures correlate with molecular methods of diagnosis. Although the study was not randomised, and patients and physicians were not blinded to treatment allocation, the investigators made the useful observation that despite apparent cure through immunological/serological outcome measures, the molecular markers persisted. This indicated that parasites were not eliminated after treatment with nitrofuran derivatives (<a href="./references#CD004102-bbs2-0008" title="BragaM , Lauria-PiresL , ArgalarazE , NascimentoR , TeixeiraA . Persistent infection in chronic Chagas disease patients treated with anti-trypanosoma cruzi nitroderivatives. Revista do Instituto de Medicina Tropical de Sao Paulo2000;42:157-61. [DOI: 10.1590/s0036-46652000000300009]">Braga 2000</a>). A further paper using the same cohort of patients reported the findings of a 10‐year follow‐up of 91 people with chronic chagasic cardiomyopathy and 41 uninfected controls. Using molecular methods of competitive PCR, they found that both treated and untreated patients showed evidence of active infection (<a href="./references#CD004102-bbs2-0013" title="Lauria-PiresL , BragaM , VexenatA , NitzN , Simoes-BarbosaA , TinocoD , et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. American Journal of Tropical Medicine and Hygiene2000;63(3-4):111-8. [DOI: 10.4269/ajtmh.2000.63.111]">Lauria‐Pires 2000</a>). </p> <p>Dr Viotti and colleagues have been screening patients with Chagas disease in the Chagas disease section at Eva Peron Hospital in Buenos Aires, Argentina since 1984, and have recruited almost 2000 patients during this period. The treatment of Chagas disease has been a major concern, therefore in 1994 a published study aiming to compare the clinical and serological progress of cardiomyopathy in patients treated with benznidazole and untreated individuals was undertaken. Seventy untreated patients and 131 benznidazole‐treated patients (5 mg/kg/day for 30 days) were recruited. The follow‐up period averaged eight years. The proportion of patients who were serologically negative at the end of follow‐up was higher in the treated group than in the untreated group (19.1% versus 6%; P = 0.05). The investigators concluded that treatment with benznidazole decreases antibody titres if treatment is used early in the course of chronic chagasic cardiomyopathy (<a href="./references#CD004102-bbs2-0021" title="ViottiR , ViglianoC , ArmentiH , SeguraE . Treatment of chronic Chagas' disease with benznidazole: clinical and serological evolution of patients with long-term follow-up. American Heart Journal1994;127:151-62. [DOI: 10.1016/0002-8703(94)90521-5]">Viotti 1994</a>). </p> <p>Due to the chronic implications of Chagas disease, the effectiveness of treatment has been widely studied. In a 2006 study of 566 undetermined patients 30 to 50 years old with three positive serologies and without heart failure, 283 were treated with benznidazole (5 mg/kg/day for 30 days) and the same number remained untreated. The authors concluded that treatment of Chagas disease in the early stage of the illness prevents progression towards cardiac manifestations and increases negative seroconversion (<a href="./references#CD004102-bbs2-0022" title="ViottiR , ViglianC , LococoB , BertochiG , PettiM , AlvarezM , et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a non-randomised trial. Annals of Internal Medicine2006;144:724-34. [DOI: 10.7326/0003-4819-144-10-200605160-00006]">Viotti 2006</a>). </p> <p>In a further study of patients who became seronegative, either spontaneously or by parasitological treatment, clinical and epidemiological progression features of Chagas disease were analysed. The authors concluded that the parasitological cure is a favourable clinical course (<a href="./references#CD004102-bbs2-0006" title="BertocchiGL , ViglianoC , LococoB , PettiM , ViottiR . Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria. Transactions of the Royal Society of Tropical Medicine and Hygiene2013;107:372–6. [DOI: 10.1093/trstmh/trt029]">Bertocchi 2013</a>). Although the effectiveness of benznidazole has been widely proven, its adverse reactions have been a major cause of concern. Consequently, developing new drugs and new schemes of treatment is integral. </p> <p>In 2016, Viotti's research team conducted a pilot study to assess the efficiency of a new treatment scheme with benznidazole for individuals with chronic Chagas disease. Twenty patients were included; however, 17 were tested by PCR. All patients received 5 mg/kg/day in 2 daily doses every 5 days for 60 days. Parasitological cure was achieved in 65% of patients, whilst 50% had adverse reactions, and only one patient suspended treatment. The authors concluded that the low rate of treatment suspension was a major accomplishment of this study. However, further studies are required to confirm these results in longitudinal assessments (<a href="./references#CD004102-bbs2-0005" title="ÁlvarezM , HernándezY , BertocchiG , FernándezM , LococoB , RamírezJ , et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrobial Agents and Chemotherapy2016;60:833–7. [DOI: 10.1128/AAC.00745-15]">Alvarez 2016</a>). </p> <p>A further study from Argentina followed 198 people drawn from a larger cohort of 492 patients that had suffered attrition due to losses to follow‐up, with the aim of examining the prognosis of chronic Chagasic cardiomyopathy in treated and untreated groups undergoing prolonged follow‐ups. There were three groups: a) 32 patients treated with nifurtimox (5 to 8 mg/kg/day for 60 days); b) 36 patients treated with benznidazole (5 mg/kg/day for 30 days); and c) 130 untreated patients. All patients underwent the following tests at the beginning or during the follow‐up of the cohort study: a) three serological Chagas‐specific tests (Direct agglutination with 2‐mercaptoethanol (DA‐2ME), Indirect Haemoagglutination (IHA), or Indirect Immunofluorescence (IIF)) with titers equal to or higher than 1/32 for at least two out of the three reactions; and b) electrocardiogram and chest X‐ray. </p> <p>The patients were followed for an average of 14 years (8 to 32 years). At the outset, only 9.6% of the infected patients had cardiomyopathy; however, when comparing treated and untreated patients, the proportion of cardiomyopathy was higher in the former group (7% versus 3.2%) and reflects the use of drug treatment in those with symptomatic disease. The clinical prognosis was worse in the untreated group, with less likelihood of reductions in antibody titres (≤ 1/64 in 86% versus 38% of treated and untreated patients, respectively). These long‐term findings suggest that drug treatment is superior to no treatment (<a href="./references#CD004102-bbs2-0012" title="Fabbro de SuasnábarD , AriasE , StreigerM , PlacenzaM , IngraramoM , Del BarcoM , et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated Chagasic patients. Revista do Instituto de Medicina Tropical de Sao Paulo2000;42:99-109. [DOI: 10.1590/s0036-46652000000200007]">Fabbro 2000</a>). </p> <p>A further long‐term follow‐up (13 to 21 years) was reported in which the prognosis of acute and chronic Chagas disease was compared, with all patients receiving benznidazole. The cure criteria were established by means of quantitative serological tests that included: to complement fixation, indirect immunofluorescence, indirect haemagglutination, and ELISA. However, given the duration of follow‐up, not all of these tests were used in all of the patients. The cure rate was higher in patients with acute disease (76%) than in those with chronic disease (8% to 9%). It was concluded that the cure criteria should include parasitological as well as immunological criteria, and that new immunological tests have opened a door to a different way of studying the natural history of Chagas disease. It is challenging to make any inferences about the effects of treatment in this study since there was no randomised control group, neither patients nor physicians were blind to the treatment group, and the criteria for cure changed over the follow‐up (<a href="./references#CD004102-bbs2-0010" title="CancadoJ . Long term evaluation of etiological treatment of Chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de Sao Paulo2002;44:29-37. [DOI: 10.1590/S0036-46652002000100006 ]">Cancado 2002</a>; <a href="./references#CD004102-bbs2-0071" title="SchijmanA , BisioM , OrellanaL , SuedM , DuffyT , MejiaA , et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLOS Neglected Tropical Diseases2011;5(1):e931. [DOI: 10.1371/journal.pntd.0000931]">Schijman 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004102-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benznidazole versus placebo, Outcome 1: Clearance of antibody titres" data-id="CD004102-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Benznidazole versus placebo, Outcome 1: Clearance of antibody titres</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benznidazole versus placebo, Outcome 2: Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays" data-id="CD004102-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Benznidazole versus placebo, Outcome 2: Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benznidazole versus placebo, Outcome 3: Clinical improvement" data-id="CD004102-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Benznidazole versus placebo, Outcome 3: Clinical improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benznidazole versus placebo, Outcome 4: Adverse effects" data-id="CD004102-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Benznidazole versus placebo, Outcome 4: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004102-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/urn:x-wiley:14651858:media:CD004102:CD004102-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nifurtimox versus placebo, Outcome 1: Clearance of antibody titres" data-id="CD004102-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_t/tCD004102-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Nifurtimox versus placebo, Outcome 1: Clearance of antibody titres</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/media/CDSR/CD004102/image_n/nCD004102-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004102-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with both late‐stage, symptomatic Chagas disease and CCC<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> benznidazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Benznidazole</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance or reduction of antibody titres (N)</b> </p> <p><b>(a)</b> at 12 months </p> <p><b>(b)</b> at 2 years </p> <p><b>(c)</b> at 5 years </p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 207 per 1000</b> </p> <p><b>(b) 351 per 1000</b> </p> <p><b>(c) 439 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 395 per 1000</b> </p> <p>(339 to 457)</p> <p><b>(b) 506 per 1000</b> </p> <p>(453 to 562)</p> <p><b>(c) 548 per 1000</b> </p> <p>(500 to 601)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) RR 1.91</b> (1.64 to 2.21) </p> <p><b>(b) RR 1.44</b> </p> <p>(1.29 to 1.60)</p> <p><b>(c) RR 1.25</b> </p> <p>(1.14 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1896 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> <p>(315 to 805)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 31.66</b> </p> <p>(10.56 to 94.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>2</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological demonstration of tissue parasites (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement (N)</b> </p> <p>(a) Heart failure</p> <p>(b) Sustained ventricular tachycardia</p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 86 per 1000</b> </p> <p><b>(b) 29 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>(a) 76 per 1000</b> </p> <p>(59 to 98)</p> <p><b>(b) 23 per 1000</b> </p> <p>(15 to 36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) RR 0.89</b> </p> <p>(0.69 to 1.14)</p> <p><b>(b) RR 0.80</b> </p> <p>(0.51 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2854 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>3</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (N)</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> <p>(198 to 287)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.52</b> </p> <p>(2.09 to 3.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2854 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/>Moderate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> Peto odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for methodological limitations due to incomplete outcome reporting and one level due to imprecision (small sample size).<br/><sup>2</sup>Downgraded two levels due to selection bias, performance bias, and incomplete outcome reporting, and one level due to imprecision (small sample size).<br/><sup>3</sup>Downgraded one level for methodological limitations due to incomplete outcome reporting and one level due to imprecision (CI consistent with benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benznidazole compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004102-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with both late‐stage, symptomatic Chagas disease and CCC </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> nifurtimox </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nifurtimox</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance or reduction of antibody titres (N)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>704 per 1000</b> </p> <p>(102 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.89</b> </p> <p>(2.44 to 116.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1</sup><br/>Very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pathological demonstration of tissue parasites (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (N)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to selection bias, performance bias, and incomplete outcome reporting, and one level due to imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nifurtimox compared to placebo for treating late‐stage, symptomatic Chagas disease and CCC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/full#CD004102-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004102-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benznidazole versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clearance of antibody titres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 At 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clearance of parasitaemia, demonstrated by negative xenodiagnosis, blood culture, and/or molecular biology assays <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Sustained ventricular tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benznidazole versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004102-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nifurtimox versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clearance of antibody titres <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nifurtimox versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004102.pub3/references#CD004102-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004102.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004102-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004102-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004102-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004102-note-0007">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004102\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004102\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004102\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004102\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004102\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004102.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004102.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004102.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004102.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004102.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725173076"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004102.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725173080"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004102.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e74c1b8ff1be5',t:'MTc0MDcyNTE3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 